Similar Clinical Improvement Rates Among Biologic Drug Classes in Crohn’s Disease: Systematic Review and Meta-Regression-Reference-Cited by-同舟云学术

Similar Clinical Improvement Rates Among Biologic Drug Classes in Crohn’s Disease: Systematic Review and Meta-Regression

Published:2022-02-15 Issue:9 Volume:28 Page:1462-1464
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Hanžel Jurij¹²³,Sedano Rocio²⁴,Jeyarajah Jenny²,Zou Guangyong²⁵⁶,McFarlane Stefanie C²,Ma Christopher²⁷,Jairath Vipul²⁴⁵^ORCID

Affiliation:

1. Department of Gastroenterology, University Medical Center Ljubljana, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia

2. Alimentiv Inc , London, Ontario , Canada

3. Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Academic Medical Centre , Amsterdam , the Netherlands

4. Division of Gastroenterology, Department of Medicine, Western University , London, Ontario , Canada

5. Department of Epidemiology and Biostatistics, Western University , London, Ontario , Canada

6. Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University , London, Ontario , Canada

7. Division of Gastroenterology & Hepatology, University of Calgary , Calgary, Alberta , Canada

Abstract

Lay Summary We conducted a systematic review and metaregression of pivotal Crohn’s disease trials to evaluate the rates of change in Crohn’s Disease Activity Index scores in patients receiving biologic treatments. The speed of clinical improvement was similar among biologic drug classes.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

https://academic.oup.com/ibdjournal/advance-article-pdf/doi/10.1093/ibd/izac018/42535413/izac018.pdf

Reference9 articles.

1. Assessing drug treatment preferences of patients with Crohn’s disease;Lichtenstein;Patient.,2010

2. Heterogeneity in definitions of efficacy and safety endpoints for clinical trials of Crohn’s disease: a systematic review;C;Clin Gastroenterol Hepatol.,2018

3. Comparative efficacy and rapidity of action for infliximab vs ustekinumab in biologic naive Crohn’s disease;Narula;Clin Gastroenterol Hepatol.,2021

4. Comparative efficacy and speed of onset of action of infliximab vs golimumab in ulcerative colitis;Singh;Clin Gastroenterol Hepatol.,2020

5. Ustekinumab IV induction results in Crohn’s disease symptom improvement within the first week in anti-TNF refractory patients [A108];Sandborn;J Can Assoc Gastroenterol.,2018